TRAIL or bestatin alone slightly suppressed tumor growth by 10.98% and 15.71%, respectively, whereas a 64.62% decrease in tumor growth was surprsingly observed in the TRAIL plus bestatin treatment group, and the CDI was 0.47, thus indicating a strongly synergistic drug-drug interaction. Here, TNFSF10 is linked to neoplasm.